Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation

[1]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[2]  G. Mills,et al.  A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. , 2011, Cancer research.

[3]  G. Mills,et al.  ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.

[4]  A. Brodie,et al.  Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance , 2011, Molecular and Cellular Endocrinology.

[5]  M. Dowsett,et al.  New and translational perspectives of oestrogen deprivation in breast cancer , 2011, Molecular and Cellular Endocrinology.

[6]  K. Helzlsouer,et al.  Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy , 2011, Breast Cancer Research and Treatment.

[7]  M. Dowsett,et al.  Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. , 2011, Anticancer research.

[8]  M. Ellis,et al.  Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.

[9]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[10]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[11]  S. Johnston,et al.  Targeting endocrine resistance: is there a role for mTOR inhibition? , 2010, Clinical breast cancer.

[12]  Funda Meric-Bernstam,et al.  Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. , 2010, Clinical breast cancer.

[13]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Mills,et al.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.

[15]  D. Schaid,et al.  Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. , 2010, Cancer research.

[16]  J. Thigpen.  Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .

[17]  G. D'aiuto,et al.  Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Johnston.  Enhancing the efficacy of hormonal agents with selected targeted agents. , 2009, Clinical breast cancer.

[19]  M. Sikora,et al.  The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance , 2009, Breast Cancer Research and Treatment.

[20]  R. Santen,et al.  Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. , 2008, Advances in experimental medicine and biology.

[21]  M. Dowsett,et al.  Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Winer,et al.  Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Goss,et al.  Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy , 2007, Steroids.

[24]  F. Stossi,et al.  Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. , 2006, Molecular endocrinology.

[25]  P. Goss,et al.  Lapatinib: current status and future directions in breast cancer. , 2006, The oncologist.

[26]  M. Dowsett,et al.  Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. , 2005, Endocrine-related cancer.

[27]  Marc E. Lippman,et al.  GREB1 is a critical regulator of hormone dependent breast cancer growth , 2005, Breast Cancer Research and Treatment.

[28]  F. Labrie,et al.  Androstenedione and androst-5-ene-3β,17β-diol stimulate DMBA-induced rat mammary tumors — role of aromatase , 2005, Breast Cancer Research and Treatment.

[29]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[30]  M. Dowsett,et al.  The pharmacology of letrozole , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[32]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[33]  A. Brodie,et al.  The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[35]  K. Takano,et al.  Estrogenic impurities in labware , 2001, Nature Biotechnology.

[36]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[37]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[38]  W. Bartsch,et al.  Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. , 1986, Journal of Steroid Biochemistry.

[39]  M. Lippman,et al.  The effects of 17 beta estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium. , 1980, European journal of cancer.